BioNTech stock falls as earnings beat expectations, but show falling demand for COVID-19 vaccines

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

Business News News

Business Business Latest News,Business Business Headlines

The U.S.-listed shares of BioNTech SE fell 2.7% in premarket expectations, as profit and revenue beat expectations but fell from a year ago due to lower...

The U.S.-listed shares of BioNTech SE BNTX fell 2.7% in premarket expectations, as profit and revenue beat expectations but fell from a year ago due to lower demand for COVID-19 vaccines, and indicated demand would fall further. Net income fell to EUR2.28 billion , or EUR9.26 a share, from EUR#.17 billion, or EUR12.18 a share, in the year-ago period. The FactSet consensus for earnings per share was EUR7.78. Revenue fell 22.7% to EUR4.28 billion , above the FactSet consensus of EUR3.65 billion.

7% in premarket expectations, as profit and revenue beat expectations but fell from a year ago due to lower demand for COVID-19 vaccines, and indicated demand would fall further. Net income fell to EUR2.28 billion , or EUR9.26 a share, from EUR#.17 billion, or EUR12.18 a share, in the year-ago period. The FactSet consensus for earnings per share was EUR7.78. Revenue fell 22.7% to EUR4.28 billion , above the FactSet consensus of EUR3.65 billion.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

I wonder why...

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines